Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Insmed reported Q2 2026 total revenue of $425.5 million, a 296% increase year-over-year, driven by BRINSUPRI sales of $309.2 million which grew 49% quarter-over-quarter. The company raised its 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion and increased its peak revenue estimate for its three lead programs to more than $14 billion total.
Key figures
- Revenue
- 425500000
- Guidance
- 2026 BRINSUPRI revenue $1.25B-$1.40B (raised from at least $1B); 2026 ARIKAYCE revenue $450M-$470M
- Revenue Yoy
- 296%
- Cash position
- 1200000000
- Arikayce revenue
- 116300000
- Brinsupri revenue
- 309200000
- Arikayce yoy growth
- 8%
- Peak sales estimate
- 14000000000
- Brinsupri qoq growth
- 49%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.